keyword
MENU ▼
Read by QxMD icon Read
search

mantle lymphoma

keyword
https://www.readbyqxmd.com/read/29348844/trends-and-variations-in-mantle-cell-lymphoma-incidence-from-1995-to-2013-a-comparative-study-between-texas-and-national-seer-areas
#1
Shuangshuang Fu, Michael Wang, David R Lairson, Ruosha Li, Bo Zhao, Xianglin L Du
Background: Few studies have assessed mantle cell lymphoma (MCL) incidence trends in the U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) areas. Previous studies were 5 to 9 years old and MCL incidence in Texas remains unknown. This study updated the temporal trends and variations of MCL incidence in the SEER areas and compared them with counterpart data in Texas. Results: From 1995 to 2013, there were 2, 435 and 5, 193 newly diagnosed MCL patients in Texas and SEER areas...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29348312/composite-morphologically-and-immunohistochemically-distinct-classical-and-pleomorphic-mantle-cell-lymphomas
#2
Huan-You Wang, Richard L Wong
No abstract text is available yet for this article.
January 18, 2018: Blood
https://www.readbyqxmd.com/read/29338540/efficacy-and-safety-of-frontline-rituximab-cyclophosphamide-doxorubicin-and-prednisone-plus-bortezomib-vr-cap-or-vincristine-r-chop-in-a-subset-of-newly-diagnosed-mantle-cell-lymphoma-patients-medically-eligible-for-transplantation-in-the-randomized-phase-3
#3
Johannes Drach, Huiqiang Huang, Olga Samoilova, Andrew Belch, Charles Farber, André Bosly, Jan Novak, Jan Zaucha, Angela Dascalescu, Udomsak Bunworasate, Zvenyslava Masliak, Kateryna Vilchevskaya, Tadeusz Robak, Lixia Pei, Brendan Rooney, Helgi van de Velde, Franco Cavalli
This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive stem cell transplantation (SCT) despite medical eligibility. Complete response (CR)/unconfirmed CR (CRu) rates were 67 vs. 39% (odds ratio 3.69 [95% CI(confidence interval): 1.31, 10...
January 17, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29335632/long-term-outcome-analysis-of-reduced-intensity-allogeneic-stem-cell-transplantation-in-patients-with-mantle-cell-lymphoma-a-retrospective-study-from-the-ebmt-lymphoma-working-party
#4
Stephen P Robinson, Ariane Boumendil, Herve Finel, Karl S Peggs, Patrice Chevallier, Jorge Sierra, Jürgen Finke, Xavier Poiré, Natacha Maillard, Noël Milpied, Ibrahim Yakoub-Agha, Mickey Koh, Nicolaus Kröger, Arnon Nagler, Yener Koc, Sascha Dietrich, Silvia Montoto, Peter Dreger
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%...
January 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29333021/efficacy-and-safety-of-ibrutinib-in-indian-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cases-from-a-named-patient-program
#5
Mohan B Agarwal, Dinesh Bhurani, Chirag Shah, Nitin Sood, Manish Singhal, Anil Kamat, Subash Chezhian, Suryaprakash Mishra, Dinesh Nagrale
Context: This named patient program evaluated the safety and efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase in Indian patients with relapsed/refractory chronic lymphocytic leukemia (CLL, with/without chromosome 17 deletion [del17p]) and mantle cell lymphoma (MCL). Subjects and Methods: The eight enrolled patients (relapsed/refractory CLL: n = 6 [4/6 patients with del17p] and relapsed/refractory MCL: n = 2) had median age of 55 years (range, 52-60) and had received a median of 3 (CLL patients) and 4 (MCL patients) prior therapies...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29325898/treatment-of-mantle-cell-lymphoma-in-older-adults
#6
REVIEW
Daniel F Pease, Vicki A Morrison
Mantle cell lymphoma (MCL) predominantly affects older adults, with a median age at diagnosis of 70years. A frequently aggressive yet incurable lymphoma, the goal of therapy for MCL is to turn a potentially life-threatening illness into a chronic disease with prolonged periods of remission. Large randomized trial data supports the standard treatment in younger patients of cytarabine-based induction followed by autologous stem cell transplant. Most patients will not be eligible for this intensive approach based on older age, comorbidities, and functional status, making the geriatric assessment an essential step in choosing the appropriate strategy...
January 8, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29325245/-clinical-characteristics-of-high-grade-b-cell-lymphomas-with-rearrangement-of-myc-bcl-6-and-bcl-2
#7
J Y Gong, Y Z Zhang, J D Zhang, W Zhang, J Q Li, K Ru, E B Liu
Objective: To investigate the clinicopathologic features of patients with high-grade B-cell lymphomas (HGBL) that have rearrangements of MYC, bcl-6 and bcl-2. Methods: One hundred and fifty-eight B-cell lymphomas patients from Institute of Hematology and Blood Diseases Hospital from January 2016 to April 2017 were detected by fluorescence in situ hybridization (FISH) with double color split-apart probes. Results: Among 158 B-cell lymphomas, 3 cases with MYC, bcl-2 and bcl-6 rearrangements were identified, 1 of which also had CCND1/IgH translocation...
January 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29320913/a-phase-2-study-of-rituximab-cyclophosphamide-bortezomib-and-dexamethasone-r-cybord-in-relapsed-low-grade-and-mantle-cell-lymphoma
#8
Mohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, Allison C Rosenthal, Christopher R Conley, Heidi E Kosiorek, Brenda F Ginos, Katherine M Gano, Craig S Nichols, Jose F Leis, Patrick B Johnston, Thomas M Habermann, Donald W Northfelt, Peter Leif Bergsagel, David J Inwards, Thomas E Witzig, Stephen M Ansell, Craig B Reeder
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5)...
January 10, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29316585/-malignant-b-cell-lymphoma-advances-in-the-therapy-of-follicular-lymphoma-and-mantle-cell-lymphoma
#9
Christian Buske, Martin Dreyling
No abstract text is available yet for this article.
January 2018: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29315093/the-first-case-of-lupus-nephritis-developing-in-a-patient-with-mantle-cell-lymphoma
#10
Taro Horino, Yuki Osakabe, Mio Matsuura, Osamu Ichii, Yoshio Terada
No abstract text is available yet for this article.
January 9, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29310379/male-breast-cancer-and-mantle-cell-lymphoma-in-a-single-patient-a-case-report-and-literature-review
#11
Jun Liu, Hongquan Wei, Keqing Zhu, Liqin Lai, Xiaoyu Han, Yue Yang
RATIONALE: Although still relatively rare, multiple primary malignant neoplasms (MPMNs) have been increasingly reported in recent years. PATIENT CONCERNS AND DIAGNOSES: A 65-year-old man was referred to our hospital for a painless, incidental left axillary lump. Ultrasound showed enlarged left axillary lymph nodes. An excisional biopsy was conducted on 3 lymph nodes. The pathological diagnosis was determined to be metastatic adenocarcinoma and mantle cell lymphoma (MCL) in the lymph nodes...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29301121/association-of-soluble-interleukin-2-receptor-and-c-reactive-protein-with-the-efficacy-of-bendamustine-salvage-treatment-for-indolent-lymphomas-and-mantle-cell-lymphoma
#12
Yukiko Kawaguchi, Tsuyoshi Nakamaki, Maasa Abe, Yuta Baba, So Murai, Megumi Watanuki, Nana Arai, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Hiroshi Harada, Bungo Saito
Bendamustine has demonstrated favourable efficacy in relapsed or refractory indolent lymphoma and mantle cell lymphoma. We retrospectively evaluated the pre-treatment clinical and laboratory factors and their correlation with the clinical outcome of these lymphomas. We analysed 53 patients who had been treated with bendamustine alone (n = 6) or rituximab plus bendamustine (n = 47). The overall response rate was 81.1%, with a complete response (CR) rate of 39.6%. The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0...
January 5, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/29296874/crosstalk-between-ror1-and-bcr-pathways-defines-novel-treatment-strategies-in-mantle-cell-lymphoma
#13
Hanna Karvonen, David Chiron, Wilhelmiina Niininen, Sara Ek, Mats Jerkeman, Elaheh Moradi, Matti Nykter, Caroline A Heckman, Olli Kallioniemi, Astrid Murumägi, Daniela Ungureanu
Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin B-cell lymphoma with poor prognosis due to drug resistance. Introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has markedly improved MCL therapy outcome, but drug resistance remains a challenge. The selective cell-surface expression of oncogenic receptor tyrosine kinase-like orphan receptor 1 (ROR1) pseudokinase in hematological malignancies has made this receptor a promising candidate for targeted therapy. We sought to identify the molecular mechanism underlying divergent ROR1-mediated apoptotic responses in MCL cell lines and primary samples...
November 14, 2017: Blood Advances
https://www.readbyqxmd.com/read/29296850/progressive-multifocal-leukoencephalopathy-and-hematologic-malignancies-a-single-cancer-center-retrospective-review
#14
Elizabeth C Neil, Lisa M DeAngelis
Progressive multifocal leukoencephalopathy (PML) is an uncommon opportunistic infection with high morbidity and mortality. This is an institutional review board-approved retrospective review of medical records identified by diagnostic coding for PML or John Cunningham virus (JCV) from 2000 to 2015. Inclusion criteria were cerebrospinal fluid (CSF) positive for JCV by polymerase chain reaction or brain biopsy-proven PML in non-HIV patients. There were 16 patients, 12 of whom were men (75%); the median age was 56 years (range, 31-71 years)...
October 24, 2017: Blood Advances
https://www.readbyqxmd.com/read/29287939/phosphoinositide-dependent-protein-kinase-1-is-a-potential-novel-therapeutic-target-in-mantle-cell-lymphoma
#15
Saori Maegawa, Yoshiaki Chinen, Yuji Shimura, Kazuna Tanba, Tomoko Takimoto, Yoshimi Mizuno, Yayoi Matsumura-Kimoto, Saeko Kuwahara-Ota, Taku Tsukamoto, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda
Mantle cell lymphoma (MCL) is a relatively rare subtype of B-cell non-Hodgkin lymphoma (NHL) that has a poor prognosis, despite recent advances in immunochemotherapy and molecular targeted therapeutics against NHL. Therefore, development of a new therapeutic strategy for MCL is urgently needed. In this study, we first show that 3-phosphoinositide-dependent protein kinase 1 (PDPK1), an oncogenic serine-threonine protein kinase, is commonly expressed in its phosphorylated activate form in patient-derived tumor cells of various types of B-cell NHL cells, including diffuse large B cell lymphoma, follicular lymphoma and MCL...
December 26, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/29284118/danfin-functions-as-an-inhibitor-of-transcription-factor-nf-%C3%AE%C2%BAb-and-potentiates-the-antitumor-effect-of-bortezomib-in-multiple-myeloma
#16
Atsushi Uematsu, Kohki Kido, Erika Manabe, Hiroyuki Takeda, Hirotaka Takahashi, Minoru Hayashi, Yuuki Imai, Tatsuya Sawasaki
Nuclear factor-κB (NF-κB) proteins are transcription factors that play key roles in regulating most immune responses and cell death. Constitutively active NF-κB has been shown to exhibit chemoresistance by inducing anti-apoptosis in tumor cells. Multiple myeloma is known as a constitutive NF-κB activating disease, and the proteasome inhibitor bortezomib is used to treat multiple myeloma and mantle cell lymphoma. We demonstrate here that DANFIN (N,N'-bis-(2,4-dimethyl-phenyl)-ethane-1,2-diamine) functions as an inhibitor of the p65 family proteins and induces chemosensitization to bortezomib in multiple myeloma...
December 25, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29282771/consistency-of-the-moreau-cll-score
#17
Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Evarist Feliu, Jordi Junca
BACKGROUND: The Moreau score is essential for the diagnosis of B-cell lymphoproliferative disorders (B-LPD). METHODS: We assessed the consistency of the Moreau score in a series of 138 patients with at least two samples involved by a B-LPD (316 samples) other than germinal center-derived malignancies, hairy cell leukemia, and mantle cell lymphomas. Patients with evidence of two distinct B-LPDs were also excluded. RESULTS: We found 53 inconsistencies in 44 of 138 (32%) patients...
December 28, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/29273915/cyclin-d1-mrna-as-a-molecular-marker-for-minimal-residual-disease-monitoring-in-patients-with-mantle-cell-lymphoma
#18
M Lokvenc, Marketa Kalinova, K Forsterova, P Klener, M Trneny, E Fronkova, R Kodet
Chromosomal translocation t(11;14)(q13;q32) is a characteristic molecular marker of mantle cell lymphoma (MCL) and leads to the fusion of the immunoglobulin heavy chain enhancer-promoter with the cyclin D1 gene. Both aberrant cyclin D1 expression and underlying chromosomal aberration may be used as molecular targets for monitoring minimal residual disease (MRD). The present study aims to assess the usefulness of quantitative cyclin D1 gene expression compared to the standardised but more technologically demanding DNA-based method for immunoglobulin heavy chain (IGH) or t(11;14) clone-specific gene rearrangement quantification in a cohort of bone marrow (BM) and peripheral blood (PB) samples from patients with MCL...
December 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29259834/a-patient-with-non-hodgkin-lymphoma-and-nonspecific-interstitial-pneumonia-during-ibrutinib-therapy
#19
Sven Jungmann, Wolf-Dieter Ludwig, Nicolas Schönfeld, Torsten-Gerriet Blum, Claudia Großwendt, Christian Boch, Beate Rehbock, Sergej Griff, Alexander Schmittel, Torsten T Bauer
We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by rituximab maintenance therapy. Respiratory tract complications of ibrutinib other than infectious pneumonia have not been mentioned in larger trials, but individual case reports hinted to a possible association with the development of pneumonitis. In our patient, the onset of alveolitis that progressed towards NSIP together with the onset of ibrutinib treatment suggests causality...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29246179/smoldering-mantle-cell-lymphoma
#20
REVIEW
Haige Ye, Aakash Desai, Dongfeng Zeng, Krystle Nomie, Jorge Romaguera, Makhdum Ahmed, Michael L Wang
BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a long time without any treatment. The process of "wait and watch" leaves these patients with the potential risk of evolution to classic, aggressive MCL. On the other hand, early treatment for these patients may not impact overall survival but rather affects the quality of life...
December 15, 2017: Journal of Experimental & Clinical Cancer Research: CR
keyword
keyword
38851
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"